{"id":38719,"date":"2020-08-28T07:35:22","date_gmt":"2020-08-28T07:35:22","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=38719"},"modified":"2020-08-28T09:12:38","modified_gmt":"2020-08-28T09:12:38","slug":"us-fda-approves-dolutegravir-lamivudine-dovato-as-switch-option","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/38719","title":{"rendered":"US FDA approves dolutegravir\/lamivudine (Dovato) as switch option"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 6 August 2020, the US FDA extended the indication for the two-drug fixed dose combination of dolutegravir\/lamivudine (DTG\/3TC) to include use as a switch combination for people stable on other treatment.<\/strong><\/p>\n<p>DTG\/3TC was initially only approved by the FDA in April 2019 as first-line antiretroviral treatment (ART).<\/p>\n<p>The new use as a switch option is restricted to people who have an undetectable viral load on their current ART, and who do not have a history of treatment failure or resistance to either drug.<\/p>\n<p>In Europe, DTG\/3TC is already approved as both first-line ART and as a switch option so long as there is no resistance to either drug.<\/p>\n<p>Dolutegravir\/3TC is manufactured by ViiV Healthcare and is marketed with the tradename Dovato.<\/p>\n<p>For full details see the full product characteristics. [2]<\/p>\n<p>Reference<\/p>\n<ol>\n<li>ViiV press release. ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir\/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1. (6 August 2020).<br \/>\n<a href=\"https:\/\/viivhealthcare.com\/en-us\/us-news\/us-articles\/2020\/viiv-healthcare-announces-fda-approval-of-an-expanded-indication\">https:\/\/viivhealthcare.com\/en-us\/us-news\/us-articles\/2020\/viiv-healthcare-announces-fda-approval-of-an-expanded-indication<\/a><\/li>\n<li>ViiV Healthcare. US prescribing information for Dovato. (8 April 2019).<br \/>\n<a href=\"https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Dovato\/pdf\/DOVATO-PI-PIL.PDF\" rel=\"noopener noreferrer\">https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Dovato\/pdf\/DOVATO-PI-PIL.PDF<\/a> (pdf)<\/li>\n<\/ol>\n<p><em>This article was originally posted on 7 August 2020.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 6 August 2020, the US FDA extended the indication for the two-drug fixed dose combination of dolutegravir\/lamivudine (DTG\/3TC) to include use as a switch combination for people stable on other treatment. DTG\/3TC was initially only &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-38719","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=38719"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38719\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=38719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=38719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=38719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}